Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.41 |
| ▸ | FEN1 | P39748 | 4/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933579 | 0.97 | FEN1 (0.43) | LDHAALOX5APFEN1BAZ2BHPGDS | |
| SCHEMBL19794461 | 0.89 | ALOX5AP (0.40) | LDHAALOX5APFEN1HSD17B1HSD17B2 | |
| SCHEMBL19933615 | 0.89 | ALOX5AP (0.40) | ALOX5APFEN1HSD17B1HSD17B2PTGS2 | |
| SCHEMBL21721916 | 0.88 | ALOX5AP (0.39) | LDHAALOX5APFEN1BAZ2BHSD17B1 | |
| SCHEMBL21398041 | 0.88 | HPGDS (0.36) | LDHAALOX5APFEN1BAZ2BHPGDS | |
| SCHEMBL19794432 | 0.85 | MEN1 (0.47) | LDHAALOX5APFEN1BAZ2BHPGDS | |
| SCHEMBL21125647 | 0.85 | TRPV1 (0.40) | ALOX5APFEN1HPGDS | |
| SCHEMBL18015302 | 0.85 | HSD17B1 (0.39) | LDHAALOX5APFEN1BAZ2BHPGDS | |
| SCHEMBL18015574 | 0.84 | LDHA (0.52) | LDHAFEN1BAZ2BHPGDSHSD17B1 | |
| SCHEMBL19933578 | 0.84 | LDHA (0.52) | LDHAFEN1BAZ2BHPGDSHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | LDHA 2726/4885ALOX5AP 3447/4885FEN1 1267/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | LDHA 1917/4885ALOX5AP 4001/4885FEN1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.